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, with trunk adiposity especially prevalent [3, 8, [9] [10] [11] [12] [17] [18] . These changes in body composition, as well as exacerbating mortality and co-morbidity risk [15] [16] [17] [18] [19] , also contribute significantly to disability [7, [20] [21] [22] .
In recent years, individually tailored treatment strategies featuring early and aggressive DMARD use and frequent monitoring of treatment response to achieve low disease activity (LDA), preferably 'clinical remission', have been the cornerstone of pharmacologic treatment of RA. This approach, best exemplified by 'treat-to-target' (T2T) [23] [24] , has been shown to be substantially more effective in controlling inflammation and arresting progression of joint damage than previous treatment regimens [23] [24] [25] [26] . Given that rheumatoid cachexia is thought to be driven by DA, and inflammation in particular [3, [14] [15] 27] , it would be anticipated that the tighter control of DA/inflammation achieved by T2T would attenuate rheumatoid cachexia and, as a consequence, reduce functional limitations in RA patients. Pertinently, restoration of functional ability is an explicit aim of both EULAR and ACR recommendations for T2T [23] [24] 28] . Although studies assessing body composition in RA patients have been performed since the widespread use of T2T (~2008), these [26, 32-33]. However, these measures are strongly influenced by pain [34] [35] , which diminishes with T2T, and are often insensitive to changes in function in patients with controlled disease [9, 36] .
Thus, we aimed to determine whether the adverse effects of RA on body composition and physical function still exist in this era of tight control of DA. To this end, we compared body composition and objectively-assessed physical function of RA patients exclusively treated by T2T era with that of age-and sex-matched healthy sedentary controls (HC). Additionally, we compared our current findings with those previously reported by our group for stable RA patients (i.e. studies performed either before local adoption of T2T strategies, or, if more recent, on patients who commenced treatment pre-T2T [3-4, 9-12, 30]). Lastly, this investigation sought to further examine the timecourses of rheumatoid cachexia and RA disability.
METHODS
This cross-sectional study was conducted between February 2013 and March 2015, in compliance with the Helsinki Declaration, and with approval from the North Wales Research Ethics Committee -West (12/WA/0323).
Study population
RA patients with stable disease were recruited from outpatient clinics of the Peter Maddison Rheumatology Centre (PMRC), North Wales. For inclusion, participants had to: (a) fulfil the ACR 2010 revised criteria for RA [37] 
Assessments and outcome measures
Participants presented for assessments in an overnight fasted state.
Anthropometric and body composition measures
Routine anthropometric measures (body mass (BM), height, and waist and hip circumferences) were performed using standard procedures. Total and regional lean, fat, and bone masses were estimated using a whole body fan-beam DXA scanner (Hologic, QDR Discovery 45615, software V12.4), with appendicular lean mass (ALM) used as a surrogate measure of total body muscle mass [3] . The in-house co-efficient of variation (CV) of 1.4% of our scanner complies with manufacturer's guidelines.
Objective physical function
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Statistical analysis
The primary outcome of the study was ALM normalised for BM (ALM %), as this is the LM measure most relevant to performing ADL (i.e. comparing absolute ALM ignores disparities in BM and the effect fat mass (FM) has on performing ADL). The secondary outcomes included other aspects of body composition (total LM, total FM, trunk FM, and % body fat (BF%)) and the objective physical function measures.
The primary statistical analyses involved comparison of the RA group versus the HC group, Significance was set at P < 0.05 and a trend recognised as P = 0.05 -0.10. Data is presented as mean (±SD).
RESULTS
One hundred and ninety-seven (n = 197) patients with RA were deemed eligible for the study and approached. Of these, 115 (58%) declined participation (primarily due to: 'not interested' or time and/or travel constraints) leaving 82 patients who were recruited. At the time of assessment, 33 of these 82 patients had been diagnosed ≤ 12 months previously ('recent-onset' group; mean disease duration ~7 months), whilst the remaining 49 had a disease duration of 1-7 years ('established' group; mean duration ~2 years 11 months). Eighty-five age-and sex-matched sedentary HC participants were also recruited. Table 1 displays the demographic and clinical characteristics of the 82 RA patients and 85 HC participants. These groups were precisely matched for mean age (P = 0.962) and gender distribution (P = 0.992). RA patients were more frequently current (P < 0.001) or former (P < 0.001) smokers, and generally were more sedentary (P < 0.001) than the HC. With regard to DA, the mean DAS28 score was 2.8, indicating generally 'low DA', and 49% of patients had achieved a current state of 'clinical remission'. DMARD treatment is summarised in Table 1. No differences in demographic or clinical characteristics were identified between the 'recent-onset' or 'established' RA patients (data not shown), with the exception of disease duration and the proportion on combination therapy (7.1 ± 3.0 vs 34.7 ± 17.0 months, P < 0.001; and 16/33 (48%) vs 14/49 (29%), P = 0.066, respectively). 
Demographic and clinical characteristics

Anthropometry and body composition
Anthropometric and DXA-assessed body composition data appear in Table 2 . Despite being shorter (mean ~3cm, P = 0.019), RA patients were heavier (mean BM: +4.8 kg, P = 0.093), and consequently their mean BMI higher (P = 0.002), than the HC. RA patients also had a greater mean waist circumference (+7.7 cm, P = 0.001) and waist:hip ratio (P < 0.001) than HC.
When adjusted for BM (i.e. % of), RA patients had ~10% less muscle than HC (ALM %, P < 0.001).
This relative deficit corresponds with the proportional loss of ALM we observed in stable RA patients, of similar age and gender distribution, who had commenced treatment ~1992-2004 (i.e. ~9%, RA n = 23, matched HC, n = 23 [4]; ~11%, RA n = 20, matched HC, n = 20 [3]). When expressed absolutely (kg), RA patients in the current study exhibited less ALM (-1.1 kg) and TLM (-0.8 kg) than the HC, although these differences were not statistically significant.
DXA-assessed body composition confirmed that RA patients were considerably fatter than HC, with the group differences in BM more than accounted for by higher total FM in patients (+5.4 kg, 26.5% greater, P < 0.001). Consequently, BF% was also higher in patients (P < 0.001). As anticipated, the majority of this increased adiposity was situated on the trunk (+3.2 kg, 32.3% higher than HC, P = 0.001). In pre-T2T patients we had noted mean increases in total FM of ~17% [4] and ~13% [3] relative to HC.
No differences in anthropometric or DXA measures were evident between the 'recent-onset' and 'established' RA patients (data not shown; P's = 0.654 -0.998).
Objective physical function
Page 8 of 31 Rheumatology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Table   3) : IKES was 24.3% less (P < 0.001); HGS, 25.3% less (P < 0.001); STS-30, 34.2% less (P < 0.001); 8'UG, 31.1% slower (P < 0.001); and 50'W, 28.0% slower (P < 0.001). The absolute levels of performance for those tests not subject to equipment changes (i.e. STS-30, 8'UG, 50' W), achieved by RA patients in the current study are similar to those we observed in stable pre-T2T RA patients (STS-30: mean range 10.9 -14.7 repetitions, overall mean = 12.4 (vs 12.0 repetitions in the current study) [3-4, 9-12, 30-31]; 8'UG: mean range 6.0 -6.4 secs, overall mean = 6.2 (vs 7.4 secs) [4, 30-31]; 50'W mean range 9.1 -10.0 secs, overall mean = 9.5 (vs 10.7 secs) [4, 9-10, 30-31].
As with the anthropometric and body composition measures, there were no differences in performance for any of the objective function tests between the 'recent-onset' and 'established' RA patients (data not shown; P's = 0.435 -0.778).
Subjective measures of disability and health
As expected, RA patients had higher MDHAQ scores than the HC group (P = 0.001; Table 1 ).
Despite the marked impairments in objectively-assessed physical function relative to HC, the RA patients subjectively regarded themselves as only 'mildly disabled' (Table 1) . There was no difference in MDHAQ scores between 'recent-onset' and 'established' RA patients (data not shown, P = 0.880).
'Remission' versus 'non-remission' RA patients
Of the 82 RA patients, 40 had achieved clinical remission at the time of assessment (DAS28: 2.0 ± 0.4). There were no differences in age, seropositivity, disease duration or medication between 'remission' and 'non-remission' patients, however, proportionally fewer females achieved 'remission' (58% vs 71%, P = 0.187) (Table 4 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In comparison to those not in remission (DAS28: 3.6 ± 0.8), the 'remission' patients generally had slightly better body composition, albeit not significantly (Table 5) , and performed the function tests better (Table 6 ). However, even in this subgroup of highly responsive patients, body composition (i.e. waist circumference, P = 0.039; waist:hip ratio, P < 0.001; ALM, P = 0.003; ALM%, P < 0.001; total FM, P = 0.014; BF%, P = 0.001; trunk FM, P = 0.017) and objectively-assessed function (relative deficits of 13 -31%; IKES, P = 0.002; HGS, P < 0.001; STS-30, P < 0.001; 8'UG, P = 0.008; 50'W, P = 0.014) were still much worse than for HC.
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DISCUSSION
This is the first investigation of the effects on body composition and objectively-assessed physical function of current treatment regimens which aim to tightly control DA in RA patients. Overall the findings show that our T2T RA patients, including those who have achieved clinical remission, continue to have substantially reduced muscle mass, much greater levels of adiposity (especially in the trunk), and considerably worse function than sedentary age-and sex-matched healthy individuals.
These adverse effects are despite a mean DAS28 of 2.8 (an 'acceptable alternative therapeutic goal' [23] [24] ) and achievement of 'clinical remission' in approximately half our patients, both of which indicate that our cohort is well-treated and generally benefiting from the T2T approach.
Whilst the precise mechanisms underlying rheumatoid cachexia remain unclear, disease activity (i.e. inflammation) is widely accepted to be the primary driver [1, 13, 27, 29, 41] . Hence, it would be anticipated that the success of T2T in suppressing inflammation would be reflected in improved body composition in RA patients treated exclusively by this strategy relative to patients who received earlier, less clinically effective treatments. However, the proportional loss of muscle mass of ~10 % observed in our current patients relative to matched, sedentary healthy controls is similar to what we Page 10 of 31 Rheumatology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 [43] ; FM and trunk FM increased 12.5% and 13.5%, respectively, in females, and 5.4% and 7.1% in males [42] ; FM and trunk FM increased 13.5% and 21.6%, respectively, in females, with no additional adiposity in males [2]; and FM and trunk FM increased 15.3% and 19.4%, respectively, in females, with no additional adiposity in males [44] ).
Whilst the RA patients in the current study were more sedentary than the HC, the between-group difference only amounted to approximately 30 minutes walking/week, and both groups, by a distance, failed to achieve the minimum recommendation for long-term loss of FM of 250 min/week of moderate intensity physical activity (PA) [45] . This 30 minute disparity in low-moderate intensity PA would also not account for the difference in MM, as higher-intensity exercise is required to elicit hypertrophy [45] . Thus, our findings clearly indicate that rheumatoid cachexia has not been resolved, or even attenuated, by tight control of DA, despite the other clinical benefits this approach confers. We also demonstrated in this study that objectively-assessed physical function has not improved with T2T therapy. This finding is not surprising in view of the lack of improvement in either muscle mass or fat mass, and the strong association between these and physical function in RA patients [16, [20] [21] [22] . In our T2T patients, strength relative to health controls was reduced by ~25% and the performance level of tests designed to reflect the ability to perform ADL and live independently [38] , reduced by about a third. More tellingly with regard to the effect of T2T on function, the test scores obtained by patients in the current study were not better, and in some cases were worse (8'UG, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 and may be due to reductions in pain [25] , as pain is known to strongly influence HAQ scores [34] [35] 46 ]. This discord between objectively-and subjectively-assessed function in stable RA patients, together with the underestimation RA patients have of their disability, highlights the value of objective function tests and provides further evidence of their greater sensitivity for detecting functional change in patients with well-controlled disease [9, 36] .
A key aim of T2T is the "normalisation of function" (e.g. "Overarching principal" B; EULAR/International Task Force Recommendations [23] [24] ; ACR [28]). Our findings indicate that T2T has made inadequate progress in achieving this, even for patients achieving 'remission' (DAS28 = 2.0 ± 0.4; whose performance of function tests was approximately 1/5 th -1/3 rd poorer than sedentary HC). Additionally, we may have underestimated the extent of functional loss (and the perturbations in body composition) existing in broader RA populations as low DA and a high remission rate were achieved for our patients primarily with DMARD monotherapy, and no recourse to biologics, indicating that our cohort generally only has mild-moderate, and responsive, disease.
Another point to raise is the failure of widely-used measures of treatment efficacy for T2T (e.g. DAS28) to assess function, either objectively or subjectively, which is counter to both the prominence that restoration of physical function has amongst the goals of this treatment, and the strong associations function has with morbidity, mortality, treatment costs and patient quality of life in RA [47] .
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